JP2019504868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504868A5 JP2019504868A5 JP2018543090A JP2018543090A JP2019504868A5 JP 2019504868 A5 JP2019504868 A5 JP 2019504868A5 JP 2018543090 A JP2018543090 A JP 2018543090A JP 2018543090 A JP2018543090 A JP 2018543090A JP 2019504868 A5 JP2019504868 A5 JP 2019504868A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- vector according
- viral vector
- sequence
- grna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013603 viral vector Substances 0.000 claims 15
- 239000013598 vector Substances 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 9
- 108020005004 Guide RNA Proteins 0.000 claims 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 241001430294 unidentified retrovirus Species 0.000 claims 3
- 108091032955 Bacterial small RNA Proteins 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 239000013607 AAV vector Substances 0.000 claims 1
- 241000649044 Adeno-associated virus 9 Species 0.000 claims 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 241000713730 Equine infectious anemia virus Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 1
- 241000713311 Simian immunodeficiency virus Species 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 241000713325 Visna/maedi virus Species 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295390P | 2016-02-15 | 2016-02-15 | |
| US62/295,390 | 2016-02-15 | ||
| US201662298722P | 2016-02-23 | 2016-02-23 | |
| US62/298,722 | 2016-02-23 | ||
| US201662337994P | 2016-05-18 | 2016-05-18 | |
| US62/337,994 | 2016-05-18 | ||
| US201662345520P | 2016-06-03 | 2016-06-03 | |
| US62/345,520 | 2016-06-03 | ||
| US201662363625P | 2016-07-18 | 2016-07-18 | |
| US62/363,625 | 2016-07-18 | ||
| US201662410496P | 2016-10-20 | 2016-10-20 | |
| US62/410,496 | 2016-10-20 | ||
| PCT/US2017/017652 WO2017142835A1 (en) | 2016-02-15 | 2017-02-13 | Excision of retroviral nucleic acid sequences |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504868A JP2019504868A (ja) | 2019-02-21 |
| JP2019504868A5 true JP2019504868A5 (enExample) | 2020-03-26 |
| JP7176737B2 JP7176737B2 (ja) | 2022-11-22 |
Family
ID=59626223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543090A Active JP7176737B2 (ja) | 2016-02-15 | 2017-02-13 | レトロウイルス核酸配列の切除 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12122997B2 (enExample) |
| EP (1) | EP3417062B1 (enExample) |
| JP (1) | JP7176737B2 (enExample) |
| CN (1) | CN109415728A (enExample) |
| AU (1) | AU2017219605B2 (enExample) |
| CA (1) | CA3014631A1 (enExample) |
| MX (2) | MX2018009904A (enExample) |
| WO (1) | WO2017142835A1 (enExample) |
| ZA (2) | ZA201806060B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| AU2014312123A1 (en) | 2013-08-29 | 2016-03-17 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| KR102553518B1 (ko) | 2015-06-01 | 2023-07-07 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Hiv 감염의 rna-가이드된 치료를 위한 방법 및 조성물 |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| EP3417062B1 (en) | 2016-02-15 | 2024-06-26 | Temple University - Of The Commonwealth System of Higher Education | Excision of retroviral nucleic acid sequences |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| AU2021230546A1 (en) | 2020-03-04 | 2022-10-13 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| CN113528514B (zh) * | 2020-04-22 | 2023-05-05 | 中国科学院分子植物科学卓越创新中心 | 基于CRISPR-Cas12a干预阻断病毒逆转录转座的技术 |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| JP2023544382A (ja) * | 2020-10-02 | 2023-10-23 | テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｒｎａによる単純ヘルペスｉ型およびその他の関連するヒトヘルペスウイルスの根絶 |
| WO2022256294A1 (en) * | 2021-06-01 | 2022-12-08 | University Of Massachusetts | Cas9 nickase-mediated gene editing |
| US20240342106A1 (en) * | 2021-07-27 | 2024-10-17 | University Of Miami | Nanoparticles and uses thereof for treatment of human immunodeficiency virus |
| CA3231677A1 (en) | 2021-09-08 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP2485759A4 (en) | 2009-10-09 | 2013-07-24 | Univ New York | METHOD, AGENTS AND PEPTIDES FOR GENERATING A BORN IMMUNE RESPONSE IN HIV VACCINATION |
| KR20150105956A (ko) * | 2012-12-12 | 2015-09-18 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화 |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| AU2014312123A1 (en) * | 2013-08-29 | 2016-03-17 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| CN104726449A (zh) * | 2015-03-23 | 2015-06-24 | 国家纳米科学中心 | 一种用于预防和/或治疗HIV的CRISPR-Cas9系统及其制备方法和用途 |
| EP3417062B1 (en) | 2016-02-15 | 2024-06-26 | Temple University - Of The Commonwealth System of Higher Education | Excision of retroviral nucleic acid sequences |
-
2017
- 2017-02-13 EP EP17753686.9A patent/EP3417062B1/en active Active
- 2017-02-13 CN CN201780023772.9A patent/CN109415728A/zh active Pending
- 2017-02-13 MX MX2018009904A patent/MX2018009904A/es unknown
- 2017-02-13 WO PCT/US2017/017652 patent/WO2017142835A1/en not_active Ceased
- 2017-02-13 CA CA3014631A patent/CA3014631A1/en active Pending
- 2017-02-13 JP JP2018543090A patent/JP7176737B2/ja active Active
- 2017-02-13 US US15/998,558 patent/US12122997B2/en active Active
- 2017-02-13 AU AU2017219605A patent/AU2017219605B2/en active Active
-
2018
- 2018-08-15 MX MX2023005397A patent/MX2023005397A/es unknown
- 2018-09-10 ZA ZA2018/06060A patent/ZA201806060B/en unknown
-
2020
- 2020-07-10 US US16/926,427 patent/US20200392487A1/en not_active Abandoned
-
2022
- 2022-06-01 ZA ZA2022/06102A patent/ZA202206102B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504868A5 (enExample) | ||
| Mangeot et al. | Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells | |
| Barouch et al. | A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates | |
| Merten et al. | Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application | |
| Alpert et al. | ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIVmac251 challenge | |
| Casimiro et al. | Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene | |
| Doria-Rose et al. | Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge | |
| RU2018130640A (ru) | Способы и композиции для направляемого рнк лечения вич-инфекции | |
| Aguchi et al. | Sequence Note: Identification of a New HIV-2 Subtype Based on Phylogenetic Analysis of Full-Length Genomic Sequence | |
| JP2018516572A5 (enExample) | ||
| Takeda et al. | Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model | |
| Evans et al. | Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239 | |
| CA2387182A1 (en) | Lentiviral vectors for the preparation of immunotherapeutical compositions | |
| JP2018524335A5 (enExample) | ||
| RU2009130342A (ru) | Применение адаптированных рекомбиназ для лечения ретровирусных инфекций | |
| Hammonds et al. | Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization | |
| JP2003514565A5 (enExample) | ||
| Pal et al. | Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels | |
| Mansfield et al. | Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery | |
| Portis | Perspectives on the role of endogenous human retroviruses in autoimmune diseases | |
| Kawada et al. | Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine | |
| Patterson et al. | Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120 | |
| Verrier et al. | A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates | |
| Otten et al. | Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles | |
| Manrique et al. | Influence of mismatch of Env sequences on vaccine protection by live attenuated simian immunodeficiency virus |